The PSA test, a routine test that can detect the presence of the human immunodeficiency virus (HIV), can also be used to detect drugs.

But a new report from the National Institutes of Health (NIH) found that it was not effective at identifying new drugs.

In fact, the NIH report found that the test’s accuracy is just half of that of existing drug tests.

According to the NIH, the most effective test is a two-step assay that is based on detecting antibodies to a specific peptide in the blood of a person and then measuring the amount of this antibody.

The first step is to detect antibodies against a peptide found in the body of a specific patient, usually by measuring the blood level of the peptide and the concentration of the drug in the bloodstream.

The second step is a “detection” test.

That test detects the presence or absence of antibodies to specific peptides, proteins, or nucleic acids that are present in the sample.

In addition, a new test is also developed called a non-human primate (NHP) test, which tests antibodies against the same peptide that is present in human blood.

The NIH report states that a single-dose test that uses the antibody test to detect drug residues in the human body is only 100 times more accurate than using the antibody to detect a drug residue in the patient’s own body.

This means that even a single test is not accurate enough to identify new drugs, it states.

For example, the test used in the NIH study, known as the ELISA (electrolyte-lactate-lipid) test and also known as ELISA-PCR, can detect traces of drugs in the plasma of up to 80 percent of patients, while a single dose of the antibody-based test can detect a level of antibodies that is about 0.2 to 1 percent.

The ELISA test is only 99 times more specific than the ELISAs used to identify drugs in human urine.

For a person with a normal, healthy immune system, a single antibody test can be more accurate.

But when a person has a severe disease or the immune system is damaged, the ability to detect new drugs is limited.

To be more precise, a person may have one or more antibodies to drugs in their blood, but have antibodies to only one drug.

When the antibodies are mixed in the lab, the resulting compound is called a “drug cocktail.”

For example, antibodies to cocaine, a highly addictive drug, are mixed with antibodies to the stimulant methamphetamine and the other psychoactive drugs, such as heroin and amphetamine.

In some people, the combination of the two drugs may cause an immune response, resulting in the person becoming allergic to one or both drugs.

This type of drug cocktail is also known to be a drug-resistant drug, meaning that the drugs can develop resistance to existing treatments.

This is the situation that some doctors have been facing in the U.S. due to the high number of patients being treated with anti-coke and heroin medications, for example.

The study also found that while the antibody tests can detect new compounds, they cannot be used in diagnosing an individual with a chronic disease.

In fact, these tests are not used to diagnose cancer or chronic diseases.

The results can only help in the diagnosis of patients who have a genetic or environmental cause of the disease.

“This is an issue that we have had to deal with for a long time,” said Michael M. Cappella, director of the National Institute of Allergy and Infectious Diseases (NIAID), which oversees the National Center for Biotechnology Information’s National Center on HIV/AIDS.

“This report is an important step forward.”

The NIH said that it plans to improve its antibody test by using new technology and by expanding testing to more people.

The new technology will enable more tests to be administered at one time, it added.

While the study found that there is no scientific evidence that the antibody drug test is accurate, it noted that the NIH’s assessment is based upon the test that is used.

The new report will be published online in the February 11 issue of the journal Science.